Arizona State Retirement System Has $38.01 Million Holdings in Pfizer Inc. $PFE

Arizona State Retirement System raised its holdings in Pfizer Inc. (NYSE:PFE) by 1.4% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 1,578,409 shares of the biopharmaceutical company’s stock after purchasing an additional 21,200 shares during the period. Arizona State Retirement System’s holdings in Pfizer were worth $38,008,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Handelsbanken Fonder AB lifted its holdings in shares of Pfizer by 10.4% during the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after acquiring an additional 232,528 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Pfizer by 15.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock worth $132,365,000 after acquiring an additional 745,213 shares in the last quarter. Leuthold Group LLC acquired a new stake in shares of Pfizer in the second quarter valued at $4,887,000. North Dakota State Investment Board bought a new stake in Pfizer during the 4th quarter worth about $5,348,000. Finally, Park National Corp OH grew its stake in shares of Pfizer by 332.1% during the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock valued at $5,829,000 after purchasing an additional 186,053 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on PFE. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Bank of America lowered their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Guggenheim dropped their price objective on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a report on Friday, August 7th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, UBS Group reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer Trading Down 2.4%

PFE traded down $0.67 during midday trading on Tuesday, reaching $27.78. 31,737,771 shares of the company were exchanged, compared to its average volume of 41,536,398. The stock has a market capitalization of $158.34 billion, a P/E ratio of 36.55, a PEG ratio of 1.91 and a beta of 0.34. Pfizer Inc. has a one year low of $23.58 and a one year high of $29.21. The stock’s 50-day simple moving average is $26.06 and its 200 day simple moving average is $26.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.Pfizer’s revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer’s dividend payout ratio is presently 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s recent rebound was supported by a quarterly earnings report that exceeded analyst expectations on both earnings and revenue, helping restore confidence in the beaten-down pharmaceutical stock. Why Pfizer Stock Was so Healthy in August
• Positive Sentiment: Commentary remains constructive on Pfizer’s approximately 6% dividend yield and the possibility that a strengthening drug pipeline could provide upside beyond income. One analyst cited a $32.72 12-month price target, implying potential appreciation from recent levels. Forget the Dividend: This Could Be the Real Reason to Buy Pfizer Stock Now
• Positive Sentiment: Novartis India agreed to acquire Pfizer brands for $132 million, including an established hypertension treatment. The transaction could provide cash and further streamline Pfizer’s portfolio toward higher-priority products, although its overall financial impact appears limited relative to Pfizer’s size. Novartis India Acquires Pfizer Brands for $132 Million
• Neutral Sentiment: CEO Albert Bourla is scheduled to discuss Pfizer at Morgan Stanley’s Global Healthcare Conference on September 14. Investors may look for updates on the pipeline, strategy, and outlook, but no new operating information was provided in the announcement. Pfizer Invites Public to Listen to Webcast
• Negative Sentiment: Pfizer’s high yield is attracting attention, but investors are being encouraged to choose AbbVie instead because of its stronger dividend-growth profile. This reinforces concerns that Pfizer may offer income today without comparable long-term dividend growth. Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now
• Negative Sentiment: Broader commentary describes Pfizer as still struggling and highlights uncertainty surrounding its post-COVID growth strategy and next-generation drug pipeline. These concerns can limit investor enthusiasm despite the earnings beat and attractive valuation. This Is What I’d Do With Pfizer Stock Right Now

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.